These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 32444995)
1. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice. Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995 [TBL] [Abstract][Full Text] [Related]
2. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats. Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530 [TBL] [Abstract][Full Text] [Related]
3. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension. Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157 [TBL] [Abstract][Full Text] [Related]
4. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan. Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802 [TBL] [Abstract][Full Text] [Related]
5. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan. Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080 [TBL] [Abstract][Full Text] [Related]
6. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts. Burke RM; Lighthouse JK; Mickelsen DM; Small EM Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392 [TBL] [Abstract][Full Text] [Related]
8. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure. Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102 [TBL] [Abstract][Full Text] [Related]
9. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat. Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895 [TBL] [Abstract][Full Text] [Related]
10. Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation. Zhao M; Zhang J; Xu Y; Liu J; Ye J; Wang Z; Ye D; Feng Y; Xu S; Pan W; Wang M; Wan J Int Immunopharmacol; 2021 Oct; 99():108046. PubMed ID: 34435581 [TBL] [Abstract][Full Text] [Related]
11. Sacubitril/valsartan alleviates sepsis-induced myocardial injury in rats via dual angiotensin receptor-neprilysin inhibition and modulation of inflammasome/caspase 1/IL1β pathway. Refaie MMM; El-Hussieny M; Bayoumi AMA; Abdelraheem WM; Abdel-Hakeem EA; Shehata S Eur J Pharmacol; 2024 Sep; 979():176834. PubMed ID: 39038638 [TBL] [Abstract][Full Text] [Related]
12. Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress. Sorrentino A; Steinhorn B; Troncone L; Saravi SSS; Badole S; Eroglu E; Kijewski MF; Divakaran S; Di Carli M; Michel T Am J Physiol Heart Circ Physiol; 2019 Sep; 317(3):H617-H626. PubMed ID: 31298558 [TBL] [Abstract][Full Text] [Related]
13. The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice. Gao RF; Li X; Xiang HY; Yang H; Lv CY; Sun XL; Chen HZ; Gao Y; Yang JS; Luo W; Yang YQ; Tang YH Int Immunopharmacol; 2021 Jan; 90():107133. PubMed ID: 33168408 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207 [TBL] [Abstract][Full Text] [Related]
15. Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca Suetomi T; Willeford A; Brand CS; Cho Y; Ross RS; Miyamoto S; Brown JH Circulation; 2018 Nov; 138(22):2530-2544. PubMed ID: 30571348 [TBL] [Abstract][Full Text] [Related]
17. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in Myakala K; Jones BA; Wang XX; Levi M Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733 [TBL] [Abstract][Full Text] [Related]
18. Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model. Vaskova E; Ikeda G; Tada Y; Wahlquist C; Mercola M; Yang PC J Am Heart Assoc; 2020 Jul; 9(13):e015640. PubMed ID: 32538237 [TBL] [Abstract][Full Text] [Related]
19. Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice. Liu Y; Fan Y; Li J; Chen M; Chen A; Yang D; Guan X; Cao Y Biomed Pharmacother; 2021 Jan; 133():110824. PubMed ID: 33378988 [TBL] [Abstract][Full Text] [Related]
20. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts. Li X; Braza J; Mende U; Choudhary G; Zhang P Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]